Vulvar lichen sclerous treated with super potent topical corticosteroid (clobetasol propionate 0.05%)

M. Friedman, A. Weissman, H. Kerner, J. Itskovitz Eldor

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Twenty-seven patients presenting with lichen sclerosus (LS) were enrolled in this study. In 11 women, clobetasol propionate 0.05% cream (Dermovate, Glaxo) was used as a first-line therapy, while 16 patients were given the drug after the failure of other medications. Patients age ranged between 33 and 85 years and the disease lasted from 6 months to 12 years. Dermovate cream was prescribed for topical application twice a day from the beginning of the treatment, and then, if successful, as a maintenance twice a week. Minimal duration of the treatment was 19 months and the longest follow-up has been 34 months. In 25 patients (93%), dramatic success was achieved. In two cases (7%), the treatment was stopped because of local side effects. Repeated biopsies showed a histological improvement of the disease in more than 60% of the cases. Sustained treatment of LS with Dermovate, followed for a short period of time, appears to be a very effective and safe remedy.

Original languageEnglish
Pages (from-to)21-24
Number of pages4
JournalCervix and the Lower Female Genital Tract
Issue number1
StatePublished - 1994
Externally publishedYes


Dive into the research topics of 'Vulvar lichen sclerous treated with super potent topical corticosteroid (clobetasol propionate 0.05%)'. Together they form a unique fingerprint.

Cite this